EGFR and lung adenocarcinoma: These drugs have been employed in clinical use as first/second treatment line for EGFR-mutated lung adenocarcinoma patients leading to response rates and progression-free survival (PFS) ranging from 56% to 83% and 8.4‒18.9 months [82,83,84,85].